First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

Conclusion.This study demonstrates that merestinib has a tolerable safety profile and potential anticancer activity and warrants further clinical investigation.Implications for Practice.Merestinib treatment in patients with advanced cancer demonstrated an acceptable safety profile and potential antitumor activity, supporting its future development in specific disease populations as a monotherapy and/or in combination with other therapies.

Source: The Oncologist - September 10, 2019 Category: Cancer & Oncology Authors: Aiwu Ruth He, Roger B. Cohen, Crystal S. Denlinger, Ashwin Sama, Ariel Birnbaum, Jimmy Hwang, Takami Sato, Nancy Lewis, Michelle Mynderse, Michele Niland, Jennifer Giles, Johan Wallin, Brian Moser, Wei Zhang, Richard Walgren, Elizabeth R. Plimack Tags: Head and Neck Cancers, Melanoma and Cutaneous Malignancies, Gastrointestinal Cancer New Drug Development and Clinical Pharmacology Source Type: research